BioPharmSignal logoBioPharmSignal

Biotech News

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio (RLYB)RallybioFinancing

Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and

Related news

RLYBRallybio2026-06-01 12:00 EST

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

BDRXBiodexa Pharmaceuticals2026-06-30 12:00 EST

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

PTCTPTC Therapeutics, Inc.2026-06-16 03:14 EST

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

PTCTPTC Therapeutics, Inc.2026-06-15 11:00 EST

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

PHVSPharvaris2026-05-11 20:15 EST

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MGTXMeiraGTx2026-04-16 11:48 EST

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

EDITEditas Medicine2026-05-26 13:05 EST

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

PHVSPharvaris2026-05-08 10:00 EST

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

EDITEditas Medicine2026-05-26 10:15 EST

Editas Medicine Announces Proposed Public Offering

BIIBBiogen2026-05-21 22:00 EST

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

View all latest news

Rallybio

Rallybio is a rare-disease biotechnology company focused on complement and immune-mediated disorders. Its pipeline aims at high-unmet-need conditions where targeted biology matters.

Recent company news

RLYBRallybio2026-06-01 12:00 EST

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

RLYBRallybio2026-03-02 13:00 EST

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

RLYBRallybio2026-02-17 13:00 EST

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

RLYBRallybio2026-02-03 21:05 EST

Rallybio Announces Reverse Stock Split of Common Stock

RLYBRallybio2025-11-06 13:00 EST

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Stock data

Close
16.19 USD
Market cap
94.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States